What the mounjaro research actually shows — and why it matters

SURMOUNT-1: what the headline figures actually represent

The SURMOUNT-1 trial is the centrepiece of tirzepatide research for weight management. It enrolled 2,539 adults without type 2 diabetes, all with a BMI of 30 or above (or 27-plus with at least one weight-related condition), and ran for 72 weeks alongside a reduced-calorie diet and increased physical activity. At the 15mg maintenance dose, average body-weight reduction was approximately 20–21%, with some analyses reporting up to around 22.5%. Lower doses (5mg and 10mg) also produced clinically meaningful reductions, which matters for understanding how the titration schedule is designed: Mounjaro's licensed dose range runs from 2.5mg up to 15mg, with the starting dose existing primarily to let the body adjust before moving upward.

These are population averages, not individual predictions. Responses varied across the trial, as they do in clinical practice. What Mounjaro does mechanically (slowing gastric emptying, reducing appetite, influencing blood-sugar regulation through two separate receptor pathways) helps explain why the range of outcomes is wide. Genetics, baseline weight, adherence and lifestyle factors all contribute. The research establishes what is possible; it does not guarantee any single person's result.

One detail worth noting: SURMOUNT-1 was conducted alongside structured lifestyle support. The results reflect that combination, not the medicine alone. That framing holds across the wider tirzepatide research programme.

SURMOUNT-5 and the head-to-head question

Perhaps the most discussed piece of recent tirzepatide research is SURMOUNT-5, an open-label trial published in the New England Journal of Medicine in 2025. It directly compared tirzepatide with semaglutide 2.4mg (Wegovy) in 751 adults with obesity but without type 2 diabetes, over 72 weeks. Tirzepatide produced greater average weight reduction. This is significant because semaglutide 2.4mg had itself set a high bar in its own STEP 1 trial, with around 15% average weight loss, a figure that was considered landmark at the time.

NICE's appraisal committee, in publishing TA1026 in December 2024, noted that indirect comparisons across the trial evidence also favour tirzepatide. The committee recommended tirzepatide for adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower BMI thresholds applying for certain ethnic backgrounds under UK guidance. No head-to-head trial is the final word (SURMOUNT-5 was open-label and had its own limitations) but it is currently the best direct evidence available, and the NICE recommendation reflects it.

For anyone weighing up which medicine suits them, the research comparison is genuinely useful context. The clinical decision, though, involves factors the trials cannot resolve individually: existing conditions, other medicines, personal preference around injections, and tolerability.

The safety research: what clinical trials found on side effects

Clinical trials do not only measure efficacy; they are the primary source of structured safety data, and the tirzepatide programme is no exception. Across the SURMOUNT trials, the most common side effects were gastrointestinal: nausea, vomiting, diarrhoea, constipation and indigestion. These were typically most noticeable at the start of treatment or after a dose increase, and in most cases settled within days to a couple of weeks. Serious adverse events were infrequent but documented, pancreatitis among them, which led the MHRA to issue a Drug Safety Update in January 2026 reinforcing that severe or persistent stomach pain (especially if it radiates to the back) warrants urgent medical attention.

The trials also contributed data on injection-site reactions, changes in heart rate, gallbladder events and the question of thyroid effects, which informed the contraindications in the Mounjaro prescribing information. Anyone researching tirzepatide for personal use will find the NHS patient information on tirzepatide, at nhs.uk/medicines/tirzepatide, a plain-English summary of what the research established about risks.

It is also worth being clear about one boundary in the evidence base. Some searches for tirzepatide research lead to material about research-grade peptides or tirzepatide as a research chemical, these are not licensed medicines and have not undergone the clinical-trial process that Mounjaro has. The Mounjaro research programme is what underpins its MHRA licence and its NICE recommendation; those regulatory gates do not apply to unregulated analogues.

From research to clinical practice, and what that means for private treatment

The gap between a trial result and a real-world prescription involves several steps: MHRA licensing, NICE appraisal, NHS commissioning policy and, separately, private prescribing within those licensed indications. Understanding how the market for Mounjaro has evolved in the UK is part of the broader picture for anyone considering private treatment, Eli Lilly raised list prices substantially from September 2025, which affected what private providers charge.

For people who don't meet the current NHS criteria (which are phased and strict) or who prefer not to wait, a regulated private pharmacy is the licensed alternative. That still means a prescription following a proper clinical assessment, the research findings do not change that legal requirement. If you are thinking about whether tirzepatide is right for you specifically, rather than for trial populations, the appropriate place to start is a consultation with a prescriber who can map the evidence onto your individual circumstances.

Most people who speak to our clinical team find that the questions they had after reading the research are exactly the right ones to bring. If you'd like to do that, you can check your eligibility and start a free consultation, a real prescriber, not a screening algorithm, will review your answers. You can also learn more about weight-loss treatment options more broadly, or read about how tirzepatide is used in research contexts versus its licensed clinical use.